Whole transcriptional analysis identifies markers of B, T and plasma cell signaling pathways in the mesenteric adipose tissue associated with Crohn's disease.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
30 01 2020
Historique:
received: 12 10 2019
accepted: 10 01 2020
entrez: 1 2 2020
pubmed: 1 2 2020
medline: 15 5 2021
Statut: epublish

Résumé

Crohn's disease (CD) is a multifactorial disease characterized by chronic intestinal inflammation. The increased visceral adiposity near the affected intestinal area, of which mesenteric adipose tissue (MAT) is the main component, is a feature of CD. Both protective and pathological roles have been attributed to this disease-associated tissue in CD. To understand the contribution of MAT to CD pathophysiology, a molecular and cellular signature of disease-associated MAT in CD patients was provided. We performed an observational study with whole transcriptional analysis by RNA sequencing (RNA-seq) of MAT and ileal mucosa from CD patients with active disease and controls. qPCR and immunohistology were performed for validation analysis. RNA-seq identified 17 significantly regulated genes (|FC| > 1.5; FDR < 0.05) in CD-MAT compared to non-IBD controls, with a marked upregulation of plasma cell genes (i.e., IGLL5, MZB1, CD79A, POU2AF1, FCRL5, JCHAIN, DERL3, SDC1, PIM2). A less strict statistical cutoff value (|FC| > 1.5, nominal p ≤ 0.05) yielded a larger list of 651 genes in CD-MAT compared to controls. CD ileum showed the significant regulation compared to control ileum of 849 genes (|FC| > 1.5; FDR < 0.05) or 2654 genes (|FC| > 1.5, nominal p ≤ 0.05). Ingenuity Pathway Analysis revealed the significant regulation of pathways related to T- and B cell functionality in the MAT of CD patients. Despite the differences between the MAT and ileal signatures of CD patients, we identified a subset of 204 genes significantly modulated in both tissues compared to controls. This common signature included genes related to the plasma cell signature. Genes such as S100A8, S100A9 (calprotectin) and IL1B, which are associated with acute inflammatory response, were exclusively regulated in the ileal mucosa of CD disease. In contrast, some genes encoding for lymphocyte receptors such as MS4A1, CD3D and CD79A were exclusively regulated in CD-MAT, exhibiting a different pattern of immune cell activation compared to the ileal mucosa in CD patients. qPCR and immunohistology confirmed the presence of large infiltrates of CD3 Our data strongly supports the role of CD-associated MAT as a site for T-, B- and plasma cell activation, and suggests that it could also act as a reservoir of memory immune responses.

Sections du résumé

BACKGROUND
Crohn's disease (CD) is a multifactorial disease characterized by chronic intestinal inflammation. The increased visceral adiposity near the affected intestinal area, of which mesenteric adipose tissue (MAT) is the main component, is a feature of CD. Both protective and pathological roles have been attributed to this disease-associated tissue in CD. To understand the contribution of MAT to CD pathophysiology, a molecular and cellular signature of disease-associated MAT in CD patients was provided.
METHODS
We performed an observational study with whole transcriptional analysis by RNA sequencing (RNA-seq) of MAT and ileal mucosa from CD patients with active disease and controls. qPCR and immunohistology were performed for validation analysis.
RESULTS
RNA-seq identified 17 significantly regulated genes (|FC| > 1.5; FDR < 0.05) in CD-MAT compared to non-IBD controls, with a marked upregulation of plasma cell genes (i.e., IGLL5, MZB1, CD79A, POU2AF1, FCRL5, JCHAIN, DERL3, SDC1, PIM2). A less strict statistical cutoff value (|FC| > 1.5, nominal p ≤ 0.05) yielded a larger list of 651 genes in CD-MAT compared to controls. CD ileum showed the significant regulation compared to control ileum of 849 genes (|FC| > 1.5; FDR < 0.05) or 2654 genes (|FC| > 1.5, nominal p ≤ 0.05). Ingenuity Pathway Analysis revealed the significant regulation of pathways related to T- and B cell functionality in the MAT of CD patients. Despite the differences between the MAT and ileal signatures of CD patients, we identified a subset of 204 genes significantly modulated in both tissues compared to controls. This common signature included genes related to the plasma cell signature. Genes such as S100A8, S100A9 (calprotectin) and IL1B, which are associated with acute inflammatory response, were exclusively regulated in the ileal mucosa of CD disease. In contrast, some genes encoding for lymphocyte receptors such as MS4A1, CD3D and CD79A were exclusively regulated in CD-MAT, exhibiting a different pattern of immune cell activation compared to the ileal mucosa in CD patients. qPCR and immunohistology confirmed the presence of large infiltrates of CD3
CONCLUSION
Our data strongly supports the role of CD-associated MAT as a site for T-, B- and plasma cell activation, and suggests that it could also act as a reservoir of memory immune responses.

Identifiants

pubmed: 32000799
doi: 10.1186/s12967-020-02220-3
pii: 10.1186/s12967-020-02220-3
pmc: PMC6993458
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Références

J Pathol. 2000 Feb;190(2):196-202
pubmed: 10657019
Gastroenterology. 2005 Jun;128(7):2020-8
pubmed: 15940634
Nucleic Acids Res. 2007;35(16):e102
pubmed: 17702762
Inflamm Bowel Dis. 2010 May;16(5):896-902
pubmed: 19924803
Inflamm Bowel Dis. 2019 Jan 10;25(2):283-293
pubmed: 30295909
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Clin Invest. 2003 Dec;112(12):1785-8
pubmed: 14679172
Mayo Clin Proc. 2017 Jul;92(7):1088-1103
pubmed: 28601423
Gastroenterology. 1999 Jul;117(1):73-81
pubmed: 10381912
Nat Rev Genet. 2009 Jan;10(1):57-63
pubmed: 19015660
Gut. 2013 Jun;62(6):852-62
pubmed: 22543156
Immunity. 2017 Dec 19;47(6):1154-1168.e6
pubmed: 29221731
Curr Opin Gastroenterol. 2014 Nov;30(6):559-65
pubmed: 25188546
Colorectal Dis. 2015 Mar;17(3):225-34
pubmed: 25307174
Gastroenterology. 2004 Feb;126(2):414-24
pubmed: 14762777
J Crohns Colitis. 2018 Nov 9;12(10):1139-1150
pubmed: 29309546
Int J Inflam. 2017;2017:7646859
pubmed: 28487813
J Crohns Colitis. 2019 Mar 26;13(3):285-293
pubmed: 30203027
Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):103-11
pubmed: 16265128
PLoS One. 2019 Sep 26;14(9):e0223105
pubmed: 31557250
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):238-247
pubmed: 28404096
Colorectal Dis. 2012 Apr;14(4):421-8; discussion 428-30
pubmed: 22230129
Gut. 2007 Apr;56(4):577-83
pubmed: 16956921
Am J Med. 1952 Nov;13(5):583-90
pubmed: 12996536
Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):574-80
pubmed: 20625283
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1232-1241
pubmed: 30345577
Inflamm Bowel Dis. 2012 Aug;18(8):1550-7
pubmed: 22407798
Inflamm Bowel Dis. 2010 Feb;16(2):263-74
pubmed: 19653286
Clin Gastroenterol Hepatol. 2011 Aug;9(8):684-687.e1
pubmed: 21642015
J Gastrointest Surg. 2018 Dec;22(12):2125-2132
pubmed: 30043133
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Shock. 2011 Aug;36(2):121-7
pubmed: 21558985
Dig Dis Sci. 2019 Jan;64(1):204-212
pubmed: 30276568
Histopathology. 2012 Jun;60(7):1034-44
pubmed: 22008086
BMC Bioinformatics. 2009 Jan 08;10:11
pubmed: 19133141
Am J Gastroenterol. 2005 Nov;100(11):2493-502
pubmed: 16279905
Inflamm Bowel Dis. 2019 Feb 21;25(3):421-426
pubmed: 30346528
Gut. 2004 Aug;53(8):1117-22
pubmed: 15247177
PLoS One. 2014 Jun 02;9(6):e98547
pubmed: 24887376
Nutrition. 2012 Feb;28(2):113-7
pubmed: 22208553
Am J Pathol. 2016 Dec;186(12):3066-3073
pubmed: 27746181
J Crohns Colitis. 2019 Jan 1;13(1):79-91
pubmed: 30272118
J Dig Dis. 2018 Aug;19(8):475-484
pubmed: 30062772
Front Immunol. 2018 Oct 12;9:1974
pubmed: 30369924
Clin Exp Immunol. 2012 Dec;170(3):358-64
pubmed: 23121676
Eur J Immunol. 2017 Nov;47(11):1867-1874
pubmed: 28849586
Int J Colorectal Dis. 2009 Jan;24(1):1-4
pubmed: 18815796

Auteurs

Francesca Aparecida Ramos da Silva (FAR)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil.

Lívia Bitencourt Pascoal (LB)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil.

Isabella Dotti (I)

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Maria de Lourdes Setsuko Ayrizono (ML)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil.

Daniel Aguilar (D)

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Barcelona, Spain.

Bruno Lima Rodrigues (BL)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil.

Montserrat Arroyes (M)

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Elena Ferrer-Picon (E)

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Marciane Milanski (M)

Laboratory of Metabolic Disorders, School of Applied Sciences, University of Campinas (UNICAMP), Limeira, São Paulo, Brazil.

Lício Augusto Velloso (LA)

Laboratory of Cell Signaling, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

João José Fagundes (JJ)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil.

Azucena Salas (A)

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Raquel Franco Leal (RF)

IBD Research Laboratory, Colorectal Surgery Unit, Department of Surgery, School of Medical Sciences, University of Campinas (UNICAMP), Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, 13083-878, Brazil. rafranco.unicamp@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH